Clinical trials: Vehicle
- Drug or intervention Vehicle
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Subjects
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects
This study is a first-in-human phase I randomised, double-blind, placebo-controlled, evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single (IV and SC) and Multiple (IV only)…
- Trial name
- NCT03980080
- Testing
- OSE-127
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- OSE Immunotherapeutics
Rosacea
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.
- Trial name
- NCT02547441
- Testing
- CLS001 (Omiganan), Vehicle
- Where
- 41 sites in United States, Australia and 7 more
- Volunteers
- 463 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Psoriasis
Trial of HSK44459 Cream for the Management Plaque Psoriasis
Phase I Study Objectives: Primary: Assess the safety and tolerability of HSK44459 cream in 10 healthy adult participants and 10 patients with plaque psoriasis.
- Trial name
- NCT07623486
- Testing
- HSK44459 Cream, Vehicle
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Digestive System Disorders
Protocol: Phytomedicine-AMARGOL®, Clinical Trial for Efficacy Proof on Therapeutics
This is a Phase 3: Efficacy Study for AMARGOL® a phytomedicine used for asymptomatic digestive complaints.
- Trial name
- AMARGOL (NCT01485328)
- Testing
- AMARGOL®
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Laboratorio Saude Ltda.
COVID-19
The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers
Phase 1 randomized, vehicle-controlled, blinded study to assess the safety, tolerability, and PK of single ascending doses of inhaled TLC19 in healthy volunteer subjects.
- Trial name
- NCT04697654
- Testing
- TLC19, TLC19 Vehicle
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Taiwan Liposome Company
Healthy
21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation
The purpose of this study is to determine the irritancy potential of azelaic acid pre-foam formulation.
- Trial name
- NCT01430312
- Testing
- azelaic acid pre-foam formulation, Vehicle pre-foam formulation, Water
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Acne Vulgaris
Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
Therapeutic equivalence and safety study
- Trial name
- NCT02929719
- Testing
- Test., Aczone Gel 5%
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
- Trial name
- NCT02785159
- Testing
- IDP-118 Lotion, Tazorac Cream, IDP-118 Vehicle Lotion
- Where
- 14 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Healthy Volunteers
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
- Trial name
- NCT03551730
- Testing
- PRT064445/Enoxaparin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Head Lice
Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion
The purpose of the study is to determine the irritation potential of repeat applications of abametapir lotion on normal skin.
- Trial name
- NCT02061813
- Testing
- Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, Saline 0.9%
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Paroxysmal Nocturnal Hemoglobinuria
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of KP104 in healthy volunteers.
- Trial name
- NCT05490017
- Testing
- KP104
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kira Pharmacenticals (US), LLC.
Dermatitis, Atopic
Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream
Welichem Biotech has developed a small molecule drug candidate, WBI-1001, that selectively targets the pathogenic features of inflammatory skin diseases, including atopic dermatitis (a form of eczema).The purpose of this clinical…
- Trial name
- NCT01098734
- Testing
- WBI-1001
- Where
- 5 sites in Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Welichem Biotech Inc.
Healthy
DBM-1152A Inhalation Solution in Healthy Volunteers
This is a single-center, randomized, double-blind, placebo-controlled Phase 1b study to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple-dose DBM-1152A inhalation solution in healthy Chinese adults.
- Trial name
- NCT07439419
- Testing
- DBM-1152A
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
Psoriasis Vulgaris
Vasoconstriction Trial With LEO 90100 Aerosol Foam
Vasoconstriction study with LEO 90100
- Trial name
- NCT02973776
- Testing
- LEO 90100 aerosol foam, Dermoval®/Dermovate®, Diprosone
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Parkinson Disease
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.
- Trial name
- NCT06466525
- Testing
- LBT-3627
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Longevity Biotech Australia Pty Ltd (subsidiary)
Atopic Dermatitis
Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison. The goal is to determine the safety and tolerability of DBI-001 Gel vs.
- Trial name
- NCT04192513
- Testing
- J. lividum
- Where
- Dominican Republic
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DermBiont, Inc.
Frontal Fibrosing Alopecia
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
This purpose of this trial was to investigate the molecular signature of frontal fibrosing alopecia (FFA) and the effect of delgocitinib cream 2% on reversing the FFA disease signature in active lesions.
- Trial name
- NCT05332366
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Plaque Psoriasis
Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis
The purpose of this study is to compare the safety and efficacy profiles of Tazarotene Cream, 0.05% and Tazorac® (Tazarotene) Cream, 0.05% in order to demonstrate bioequivalence and to demonstrate the superiority of the 2 active…
- Trial name
- NCT02160665
- Testing
- Tazarotene Cream, 0.05%, Vehicle, Reference: Tazorac Cream, 0.05%
- Where
- United States
- Volunteers
- 866 people, healthy volunteers welcome
- Sponsor
- G & W Laboratories Inc.
Safety Issues
Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers
This study assesses the safety, tolerability and pharmacokinetics of NP10679 when delivered intravenously in escalating dose levels in comparison to placebo.
- Trial name
- NCT03565861
- Testing
- NP10679
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Neurop Inc.
Healthy Volunteers, Atopic Dermatitis
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
The study is divided in 3 parts, starting with the safety assessment of BPR277 ointment in Healthy volunteers (Part 1). If found to be well tolerated in Part 1, BPR277 ointment will be assessed in two different patients groups to…
- Conditions
- Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
- Trial name
- 3 (NCT01428297)
- Testing
- BPR277 ointment (controlled application), BPR277 ointment, BPR277
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals